WHO Drug Information Vol. 25, No. 2, 2011

WHO Drug Information Vol. 25, No. 2, 2011 Proposed INN: List 105C 19 H 26 123 IN 3 O 7 949575-24-0NHCO 2 HHOH123 IHO 2 C NHNHCO 2 Hirdabisantumirdabisantirdabisantirdabisant6-(4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}phenyl)pyridazin-3(2H)-onehistamine H 3 receptor antagonist6-(4-{3-[(2R)-2-méthylpyrrolidin-1-yl]propoxy}phényl)pyridazin-3(2H)-oneantagoniste du récepteur H 3 de l'histamine6-(4-{3-[(2R)-2-metilpirrolidin-1-il]propoxi}fenil)piridazin-3(2H)-onaantagonista del receptor H 3 de histaminaC 18 H 23 N 3 O 2 1005402-19-6NHNONOCH 3Hixekizumabum #ixekizumabixékizumabimmunoglobulin G4-kappa, anti-[Homo sapiens IL17A (interleukin17A, IL-17A)], humanized monoclonal antibody;gamma4 heavy chain (1-445) [humanized VH (Homo sapiensIGHV1-46*01 (82.70%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -Homosapiens IGHG4*01 hinge S10>P (227), CH3 K130>del (120-445)],(133-219')-disulfide with kappa light chain (1'-219') [humanizedV-KAPPA (Homo sapiens IGKV2D-29*02 (89.00%) -IGKJ2*01)[11.3.9] (1'-112') -Homo sapiens IGKC*01 (113'-219')]; (225-225":228-228")-bisdisulfide dimerimmunomodulatorimmunoglobuline G4-kappa, anti-[Homo sapiens IL17A (interleukine17A, IL-17A)], anticorps monoclonal humanisé;chaîne lourde gamma4 (1-445) [VH humanisé (Homo sapiensIGHV1-46*01 (82.70%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -Homosapiens IGHG4*01 charnière S10>P (227), CH3 K130>del (120-445)], (133-219')-disulfure avec la chaîne légère kappa (1'-219')[V-KAPPA humanisé (Homo sapiens IGKV2D-29*02 (89.00%) -IGKJ2*01) [11.3.9] (1'-112') -Homo sapiens IGKC*01 (113'-219')];dimère (225-225":228-228")-bisdisulfureimmunomodulateur175